In vitro evaluation of nanoparticle drug-coated balloons: a pectin-RGDS-OC8H17-paclitaxel solution

Abstract Drug-coated balloons have proved to be an effective technology in percutaneous transluminal angioplasty treating peripheral artery disease. Paclitaxel-based coating is mainly used. Solutions such problems as drug loss and inefficient release during operations, however, not been found yet. This study aims explore the activity of a newly designed paclitaxel-coated balloon vitro using pectin excipient (pectin-paclitaxel) compared with commercially available shellac balloon, characterize novel nanoparticle peptide (Arg-Gly-Asp-Ser, RGDS) derivative RGDS-OC 8 H 17 (pectin-RGDS-OC8H17-paclitaxel). Two solutions, pectin-paclitaxel pectin-RGDS-OC -paclitaxel, were successively prepared. The morphology both solutions was first characterized control group, balloon. Then experiments conducted determine drug-releasing profiles -paclitaxel coatings. -paclitaxel-coated smoother more homogeneous pectin-paclitaxel-coated difference obvious when paclitaxel at low concentration. During trial, curve pectin-RGDS-OC8H17-paclitaxel model showed adjustable paclitaxel-releasing: than 90% released 2 h 300 rpm 99% 10 min 1200 rpm. C ompared performance current products coating, provided higher speed. However, clinical outcomes this finding need further demonstrated. Paclitaxel-coated therapeutic strategy currently arterial disease improved terms its efficiency anti-proliferative delivery release. solution developed exhibited excellent properties. Further are still needed demonstrate drug-coated vivo importance.